Home > Boards > US OTC > Delisted >

Ocata Therapeutics Inc. (fka OCAT)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/21/2020 10:47:23 PM - Followers: 533 - Board type: Free - Posts Today: 0

 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics


Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »

Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.


Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.





Press Releases






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


#92944   Anyone know whatever happened to the trials on BearGator56 06/21/20 10:47:23 PM
#92942   Yeah Neos has done well and I expect elysse1kittycat 11/13/17 03:21:10 PM
#92941   Looks like your NEOS was a much better diannedawn 11/13/17 02:40:40 PM
#92940   Immunologic Cell Teeter-Totter* Hank615 10/27/17 02:01:18 PM
#92939   Hank615 10/27/17 02:00:10 PM
#92938   Just curious-what is the update for this company elysse1kittycat 10/12/17 09:10:51 AM
#92937   Thanks for the update. elysse1kittycat 07/09/17 09:54:49 AM
#92936   Amazed this board is still showing activity. Spideyboy 07/01/17 07:48:34 PM
#92935   Ocata Therapeutics was acquired by Astellas Pharma Inc. Renee 05/25/17 08:53:51 PM
#92934   I have a nine position in neos and elysse1kittycat 03/14/17 09:15:27 PM
#92933   It was acquired by ALPMY a while back lgoodman 02/27/17 05:13:17 PM
#92932   First message after years in the wilderness. What 2020 02/27/17 04:37:52 PM
#92931   Looking for an excellent pharmaceutical with three successful sharpei 01/28/17 09:25:43 PM
#92930   Its nice to hear from you folks and elysse1kittycat 10/07/16 12:37:54 AM
#92929   I have seen that one but don't know fulleroots 10/04/16 08:41:54 PM
#92928   XXII? north40000 10/03/16 02:03:00 AM
#92927   Yes brother still around . In on the fulleroots 10/02/16 10:12:14 AM
#92926   I check in from time to time, to All-Bidness 09/02/16 01:00:44 AM
#92925   Elysse, I invested all of the proceeds into ALPMY lgoodman 08/23/16 12:50:42 PM
#92924   Anyone still around? elysse1kittycat 08/23/16 10:43:20 AM
#92923   SHAME on the PHARMACEUTICAL Companies!! Goodbuddy4863 05/09/16 06:36:11 PM
#92922   Too early to expect miracle happenings from Astellas/Ocata north40000 03/18/16 08:37:31 AM
#92921   What is going on with Astellas. I would smokey 03/17/16 05:26:09 PM
#92920   I was excited to reinvest in OCAT or mvecho 03/16/16 04:39:18 PM
#92919   I appreciate that, I am starting my research mvecho 03/16/16 04:25:03 PM
#92918   Mvecho-I suggest you do a search on Ocata-to elysse1kittycat 03/16/16 04:19:00 PM
#92917   Hey Elysee, i have been invested in ACTC/OCAT mvecho 03/16/16 04:16:53 PM
#92916   Booski-I agree with you about the disappointing return elysse1kittycat 03/16/16 08:37:55 AM
#92915   I have to agree with you although in Booski 03/16/16 07:09:35 AM
#92914   I sure hope that anyone reading this post elysse1kittycat 03/11/16 04:54:57 PM
#92913   So ALPMY does seem to be the right pbear 03/09/16 01:07:54 PM
#92912   I have never tried this idea: Find the north40000 03/09/16 12:53:03 AM
#92911   Not much conversation on that one smokey 03/08/16 09:58:03 PM
#92910   Try placing ALPMY in the IHUB search box north40000 03/08/16 08:25:07 PM
#92909   IHUB search box and see what turns up north40000 03/08/16 08:04:03 PM
#92908   Type in the U.S. Stock symbol in the I north40000 03/08/16 08:02:47 PM
#92907   What do you mean NO smokey 03/08/16 05:20:02 PM
#92906   no Lexxy 03/08/16 05:03:25 PM
#92905   Can someone PM me about an active board smokey 03/06/16 02:21:12 PM
#92904   It's actually pretty funny how spot on and kyrie717 02/26/16 08:49:01 AM
#92903   Is the company using a 3D printer to IPO$ 02/25/16 03:31:02 PM
#92902   All I know is that I just returned elysse1kittycat 02/25/16 01:05:45 PM
#92901   ALPMY closed @ $14.10. north40000 02/24/16 09:06:42 PM
#92900   Put both symbols in a watch list, or north40000 02/24/16 07:16:33 PM
#92899   Has anyone looked at the ticker ALPMF? The joecarry 02/24/16 06:30:55 PM
#92898   Lanza is ACTC and Ocata so no big pbear 02/23/16 06:27:49 PM
#92897   The more I see and hear, the more elysse1kittycat 02/23/16 05:15:50 PM
#92896   Seems like Lanza knew all along then IMO- Dragon Lady 02/23/16 11:24:05 AM
#92894   Just another pinky R/s stock gone bad sports guy 02/22/16 09:09:04 PM
#92893   Ocata’s chief scientific officer to stay with Astellas joecarry 02/22/16 07:40:17 PM
Consent Preferences